Application of the CDK9 Inhibitor FIT-039 for the Treatment of KSHV-associated Malignancy

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2023 Jan 20

PMID 36670405

Authors

Tetsunori Sakamoto

Masahiko Ajiro

Akira Watanabe

Shingo Matsushima

Keiji Ueda

Masatoshi Hagiwara

Affiliations

Soon will be listed here.

Abstract

Chronic infection with Kaposi's sarcoma-associated herpes virus (KSHV) in B lymphocytes causes primary effusion lymphoma (PEL), the most aggressive form of KSHV-related cancer, which is resistant to conventional chemotherapy. In this study, we report that the BCBL-1 KSHV PEL cell line does not harbor oncogenic mutations responsible for its aggressive malignancy. Assuming that KSHV viral oncogenes play crucial roles in PEL proliferation, we examined the effect of cyclin-dependent kinase 9 (CDK9) inhibitor FIT-039 on KSHV viral gene expression and KSHV PEL proliferation. We found that FIT-039 treatment impaired the proliferation of KSHV PEL cells and the expression of KSHV viral genes in vitro. The effects of FIT-039 treatment on PEL cells were further evaluated in the PEL xenograft model that retains a more physiological environment for the growth of PEL growth and KSHV propagation, and we confirmed that FIT-039 administration drastically inhibited PEL growth in vivo. Our current study indicates that FIT-039 is a potential new anticancer drug targeting KSHV for PEL patients.

Citing Articles

Cartilage stem/progenitor cells-derived exosomes facilitate knee cartilage repair in a subacute osteoarthritis rat model.

Chen J, Ni X, Yang J, Yang H, Liu X, Chen M J Cell Mol Med. 2024; 28(8):e18327.

PMID: 38661437 PMC: 11044818. DOI: 10.1111/jcmm.18327.

Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA.

Zhuang A, Chen Y, Chen S, Liu W, Li Y, Zhang W Viruses. 2023; 15(12).

PMID: 38140556 PMC: 10747957. DOI: 10.3390/v15122315.

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.

Xiao L, Liu Y, Chen H, Shen L Cancer Biol Ther. 2023; 24(1):2219470.

PMID: 37272701 PMC: 10243401. DOI: 10.1080/15384047.2023.2219470.

References

Boukamp P, Petrussevska R, Breitkreutz D, Hornung J, Markham A, Fusenig N . Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol. 1988; 106(3):761-71. PMC: 2115116. DOI: 10.1083/jcb.106.3.761. View

Yao S, Hu M, Hao T, Li W, Xue X, Xue M . MiRNA-891a-5p mediates HIV-1 Tat and KSHV Orf-K1 synergistic induction of angiogenesis by activating NF-κB signaling. Nucleic Acids Res. 2015; 43(19):9362-78. PMC: 4627096. DOI: 10.1093/nar/gkv988. View

Bais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, Dias S . Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell. 2003; 3(2):131-43. DOI: 10.1016/s1535-6108(03)00024-2. View

Zhou M, Halanski M, Radonovich M, Kashanchi F, Peng J, Price D . Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. Mol Cell Biol. 2000; 20(14):5077-86. PMC: 85957. DOI: 10.1128/MCB.20.14.5077-5086.2000. View

Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A . Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet. 2006; 38(3):294-6. DOI: 10.1038/ng1749. View

Karczewski K, Weisburd B, Thomas B, Solomonson M, Ruderfer D, Kavanagh D . The ExAC browser: displaying reference data information from over 60 000 exomes. Nucleic Acids Res. 2016; 45(D1):D840-D845. PMC: 5210650. DOI: 10.1093/nar/gkw971. View

Zeng Y, Zhang X, Huang Z, Cheng L, Yao S, Qin D . Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus: role of JAK/STAT signaling. J Virol. 2006; 81(5):2401-17. PMC: 1865948. DOI: 10.1128/JVI.02024-06. View

Myoung J, Ganem D . Infection of lymphoblastoid cell lines by Kaposi's sarcoma-associated herpesvirus: critical role of cell-associated virus. J Virol. 2011; 85(19):9767-77. PMC: 3196463. DOI: 10.1128/JVI.05136-11. View

Okada S, Goto H, Yotsumoto M . Current status of treatment for primary effusion lymphoma. Intractable Rare Dis Res. 2014; 3(3):65-74. PMC: 4214239. DOI: 10.5582/irdr.2014.01010. View

10.

Yamamoto M, Onogi H, Kii I, Yoshida S, Iida K, Sakai H . CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses. J Clin Invest. 2014; 124(8):3479-88. PMC: 4109542. DOI: 10.1172/JCI73805. View

11.

Ueda K, Ishikawa K, Nishimura K, Sakakibara S, Do E, Yamanishi K . Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) replication and transcription factor activates the K9 (vIRF) gene through two distinct cis elements by a non-DNA-binding mechanism. J Virol. 2002; 76(23):12044-54. PMC: 136869. DOI: 10.1128/jvi.76.23.12044-12054.2002. View

12.

Pastore R, Chadburn A, Kripas C, Schattner E . Novel association of haemophagocytic syndrome with Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma. Br J Haematol. 2001; 111(4):1112-5. DOI: 10.1046/j.1365-2141.2000.02478.x. View

13.

Koon H, Bubley G, Pantanowitz L, Masiello D, Smith B, Crosby K . Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol. 2004; 23(5):982-9. DOI: 10.1200/JCO.2005.06.079. View

14.

Krown S, Roy D, Lee J, Dezube B, Reid E, Venkataramanan R . Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr. 2011; 59(5):447-54. PMC: 3302934. DOI: 10.1097/QAI.0b013e31823e7884. View

15.

Sharma N, Majerciak V, Kruhlak M, Yu L, Kang J, Yang A . KSHV RNA-binding protein ORF57 inhibits P-body formation to promote viral multiplication by interaction with Ago2 and GW182. Nucleic Acids Res. 2019; 47(17):9368-9385. PMC: 6755100. DOI: 10.1093/nar/gkz683. View

16.

Martorelli D, Muraro E, Merlo A, Turrini R, Fae D, Rosato A . Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders. Clin Dev Immunol. 2012; 2012:931952. PMC: 3272797. DOI: 10.1155/2012/931952. View

17.

Aguilar C, Laberiano C, Beltran B, Diaz C, Taype-Rondan A, Castillo J . Clinicopathologic characteristics and survival of patients with primary effusion lymphoma. Leuk Lymphoma. 2020; 61(9):2093-2102. DOI: 10.1080/10428194.2020.1762881. View

18.

Zhou F, Xue M, Qin D, Zhu X, Wang C, Zhu J . HIV-1 Tat promotes Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K/PTEN/AKT/GSK-3β signaling pathway. PLoS One. 2013; 8(1):e53145. PMC: 3534639. DOI: 10.1371/journal.pone.0053145. View

19.

Caselli E, Galvan M, Cassai E, Di Luca D . Transient expression of human herpesvirus-8 (Kaposi's sarcoma-associated herpesvirus) ORF50 enhances HIV-1 replication. Intervirology. 2003; 46(3):141-9. DOI: 10.1159/000071454. View

20.

Higasa K, Miyake N, Yoshimura J, Okamura K, Niihori T, Saitsu H . Human genetic variation database, a reference database of genetic variations in the Japanese population. J Hum Genet. 2016; 61(6):547-53. PMC: 4931044. DOI: 10.1038/jhg.2016.12. View